Catalog No.S7842

LY3009120 Chemical Structure

Molecular Weight(MW): 424.51

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

Size Price Stock Quantity  
USD 147 In stock
USD 477 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

5 Customer Reviews

  • B, VE or VELV were transiently transfected in SKBR3 for 24 hours. Then, the cells were treated with 1 μmol/L lapatinib for 1 hour, followed by treatment with DMSO or the RAF inhibitors indicated for 1 hour (the dose for vemurafenib, PLX7904, LY3009120, TAK632, BGB3245, and BGB3290 is 1 μmol/L; the dose for dabrafenib and PLX8394 is 300 nmol/L). Untransfected (UT) SKBR3 cells were treated with DMSO or 1 μmol/L lapatinib (lanes 1 and 2)

    Cancer Discov, 2018, 8(9):1130-1141. LY3009120 purchased from Selleck.

    (a) INA-6, MM.1S, KMS11 or U266 cells were treated for 24 h either with 50 μm of the pan-Raf inhibitor MLN-2480, or 20 μm (INA-6 and MM.1S) or 25 μm (KMS11 or U266) of the pan-Raf inhibitor LY3009120 before western analyses of MEK1/2 and ERK1/2 activation with phosphorylation-specific antibodies.

    Leukemia, 2017, 31(4):922-933. LY3009120 purchased from Selleck.

  • Immunoblotting of whole-cell lysates of WM1366 exposed to LY3009120 (1 μmol/L) and in combination with sorafenib (1 μmol/L) and aspirin (2 mmol/L) for 48 hours using specific antibodies for phospho-acetyl CoA carboxylase (p-ACC), total acetyl CoA carboxylase (t-ACC), phospho-ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2). β-Actin was used as loading control. Immunoblots were quantified using ImageJ. The ratio of phosphorylated to total protein normalized to control is shown above the respective blots.

    Clin Cancer Res, 2018, 24(5):1090-1102. LY3009120 purchased from Selleck.

    E, Attenuation of the invasion capability of control gastric cancer cells by treatment with LY3009120 (20 μmol/L), a pan-Raf inhibitor, without effect on over-Kir2.1 gastric cancer cells. Data are shown as mean ± SD (n = 5; ***, P < 0.0001, Student t test). F, Attenuation of the level of pMEK1/2 and pERK1/2 in control gastric cancer cells by LY3009120 (20 μmol/L) treatment, without effect on over-Kir2.1 gastric cancer cells.

    Cancer Res, 2018, 78(11):3041-3053. LY3009120 purchased from Selleck.

  • Treatment of two PDXs (M048R2.X2 and M063R.X2) that express the BRAFV600E/DK with 30 mg/kg dabrafenib or 15 mg/kg LY3009120 (n=8 tumors/group). Graphs represent tumor volume and dashed lines indicate start of treatment. Unpaired t test was performed at the last time point (*p < 0.05 and ***p < 0.005). Error bars indicate SD. Lower part depicts the immunoblotting for p-ERK and BRAF on M048R2.X2 and M063R.X2, treated with either dabrafenib or LY3009120 (each lane represents a tumor derived from an individual mouse).

    Cell Rep, 2016, 16(1):263-77.. LY3009120 purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
C-Raf [1]
(Cell-free assay)
BRAF(V600E) [1]
(Cell-free assay)
(Cell-free assay)
4.3 nM 5.8 nM 15 nM
In vitro

LY3009120 inhibits the cell growth of A375 and HCT116 cells with the IC50 of 9.2 and 220 μM, respectively. LY3009120 inhibits the tyrosine kinase KDR with the IC50 of 3.9 μM.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human A375 cells MoDKVJJwdGmoZYLheIlwdiCjc4PhfS=> MoXCO|IhcA>? MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHKnc3H6eZJqdiCjc4PhfUwhUUN3ME25MlIhdk1? NH3Ve2YzPTl4NUiwOC=>
human A375 cells M4rJRmZ2dmO2aX;uJIF{e2G7 MnXwNVUhdWmwcx?= M4TydmNwdXCndHn0bZZmKGKrbnTpcoch[W[oaX7peJkhfG9iRYDoRVIhcW5iaIXtZY4hSTN5NTDj[YxteyCjZoTldkAyPSCvaX7zJIlvKHC{ZYPlcoNmKG:oIFHUVEBidmGub3f1[UwhUUN3ME2wMlAzKM7:TR?= M1PYfVI2QTZ3OEC0
human A375 cells M{D4XmZ2dmO2aX;uJIF{e2G7 NHnSbHMyPSCvaX7z Mki3R49ueGW2aYTpeoUh[mmwZHnu[{Bi\m[rbnn0fUB1dyCEUlHGJIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNVUhdWmwczDpckBxemW|ZX7j[UBw\iCDVGCgZY5idG:pdXWsJGlEPTB;MD6wN|Eh|ryP MXSyOVk3PThyNB?=
human A375 cells M3zCUmZ2dmO2aX;uJIF{e2G7 M1f2RVczKGh? NYTQU4l2UW6qaXLpeIlwdiCxZjDCVmFHKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDBN|c2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSXJMKHCqb4PwbI9zgWyjdHnvckBu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgSWxKW0FiYYPzZZktKEmFNUC9NE4xOzdizszN NYPXNWhuOjV7NkW4NFQ>
human A375 cells NILLeotHfW6ldHnvckBie3OjeR?= MUGxOUBucW6| MVHDc41x\XSrdHn2[UBjcW6maX7nJIFn\mmwaYT5JJRwKFqDSzDpckBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEG1JI1qdnNiaX6gdJJme2WwY3Wgc4YhSVSSIHHuZYxw\3WnLDDJR|UxRTBwMEO5JO69VQ>? NFnjZnozPTl4NUiwOC=>
human A375 cells MUHGeY5kfGmxbjDhd5NigQ>? M{LnR|E2KG2rboO= M2LZWGNwdXCndHn0bZZmKGKrbnTpcoch[W[oaX7peJkhfG9icEO4JIlvKGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNVUhdWmwczDpckBxemW|ZX7j[UBw\iCDVGCgZY5idG:pdXWsJGlEPTB;MD6wOlEh|ryP NG\YSYQzPTl4NUiwOC=>
human HCT116 cells M{TzZmZ2dmO2aX;uJIF{e2G7 NYLvUZd6UW6qaXLpeIlwdiCxZjDLVmFUKEdzM1SgcZV1[W62IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGVTUyCyaH;zdIhwenmuYYTpc44h[nliRVzJV2EtKEmFNUC9NE4yPSEQvF2= Ml\tNlU6PjV6MES=
human HCT116 cells MnvlVJJwdGmoZYLheIlwdiCjc4PhfS=> NX;rOnU3PjdiaB?= MlT1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNkegbJJ{KGK7IILld4F7fXKrbjDhd5NigSxiSVO1NF0xNjJ{IN88US=> MXWyOVk3PThyNB?=

... Click to View More Cell Line Experimental Data

In vivo In rats bearing BRAF V600E ST019VR PDX tumors, LY3009120 (15 or 30 mg/kg, p.o.) shows a dose-dependent tumor growth inhibition. In nude rats bearing A375 xenograft, single dose oral treatment with LY3009120 (3 to 50 mg/kg, p.o.) shows a dose dependent inhibition of phospho-ERK, with a dose for 50% inhibition of phospho-ERK (EC50) of 4.36 mg/kg, with plasma concentration to achieve 50% inhibition of phospho-ERK (EC50) of 68.9 ng/mL or 165 nM.[1]


Kinase Assay:[2]
+ Expand

Kinase activity measurement using KiNativ assays:

Compounds are screened in A375 cell lysates using the ATP-based probe at 5 µM. IC50 values are reported in micromolar units. Cell pellets are resuspended in four volumes of lysis buffer [25 mM Tris pH 7.6, 150 mM NaCl, 1% CHAPS, 1% Tergitol NP-40 type, 1% v/v phosphatase inhibitor cocktail II], sonicated using a tip sonicator, and dounce homogenized. Lysates are cleared by centrifugation at 100,000 g for 30 min. The cleared lysates are filtered through a 0.22 μM syringe filter, and gel filtered into reaction buffer [20 mM Hepes pH 7.8, 150 mM NaCl, 0.1% triton X-100, 1% v/v phosphatase inhibitor cocktail II]. MnCl2 is then added to the lysate to a final concentration of 20 mM prior to inhibitor treatment and probe labeling. Final inhibitor concentrations used for IC50 determinations are 10, 1, 0.1, and 0.01 μM. ATP competition experiments are performed at 1,000, 100, 10, and 1 μM ATP. All inhibitor treatments are performed at room temperature.
Cell Research:[1]
+ Expand
  • Cell lines: A375 and HCT116 cells
  • Concentrations: 0.51 μM
  • Incubation Time: 67 h
  • Method: Briefly, cells are grown in DMEM high glucose supplemented with 10% characterized fetal bovine serum and 1% penicillin/streptomycin/L -glutamine at 37℃, 5% CO2, and 95% humidity. Cells are allowed to expand until 70-95% confluency. A serial dilution of test compound is dispensed into a 384-well black clear bottom plate. 625 cells are added per well in 50 μL of complete growth medium. Plates are incubated for 67 h at 37℃, 5% CO2 , and 95% humidity. Then, 10 μL of a 440 μM solution of resazurin in PBS is added to each well of the plate and plates are incubated for an additional 5 h at 37℃, 5% CO2, and 95% humidity. Plates are read on a Synergy2 reader using an excitation of 540 nm and an emission of 600 nm. Data are analyzed using Prism software to calculate IC 50 values.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female NIH nude rats bearing BRAF V600E ST019VR PDX tumors
  • Formulation: 20% cyclodextrin, 25 mM phosphate, pH2.0
  • Dosages: 30 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL warmed (7.06 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC Na
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 424.51


CAS No. 1454682-72-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am trying to figure out solubility of the drug LY3009120 Catalog #7842 for in vivo studies. I need some details on the formulation and how it is made to dissolve the chemical?

  • Answer:

    It can dissolve in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 1 mg/ml clearly, and in 0.5% CMC Na at 30 mg/ml as a suspension.

Raf Signaling Pathway Map

Related Raf Products

Tags: buy LY3009120 | LY3009120 supplier | purchase LY3009120 | LY3009120 cost | LY3009120 manufacturer | order LY3009120 | LY3009120 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID